Onsior® (robenacoxib) is available in two formulations, so it’s convenient to administer in the hospital and at home.
2 mg/kg (0.91 mg/lb) orally once daily for up to a maximum of 3 days. Use the lowest effective dose for the shortest duration consistent with individual response.
Administer first dose approximately 45 minutes before surgery.
2 mg/kg (0.91 mg/lb) subcutaneously once daily for up to a maximum of 3 days.
Administer first dose approximately 45 minutes prior to surgery.
Subsequent doses can be given via subcutaneous injection or interchanged with oral tablets in dogs ≥ 5.5 lbs and ≥ 4 months of age.
Onsior can be given for up to a maximum of three total doses over three days not to exceed one dose per day.
Administer the first Onsior dose approximately 45 minutes before soft-tissue surgery.
Administer (or instruct the owner to administer) the second Onsior dose approximately 24 hours after the first dose.
Administer (or instruct the owner to administer) the third Onsior dose approximately 24 hours after the second dose.
Onsior® (robenacoxib) injection for dogs is indicated for the control of postoperative pain and inflammation associated with soft tissue surgery in dogs ≥ 4 months of age; for up to a maximum of 3 days.
Onsior® (robenacoxib) Tablets for Dogs are approved for the control of postoperative pain and inflammation associated with soft tissue surgery in dogs ≥ 5.5 lbs (2.5 kg) and ≥ 4 months of age; for up to a maximum of 3 days.
Do not use in dogs that have a hypersensitivity to robenacoxib or known intolerance to NSAIDs. Not for use in humans. Keep this and all drugs out of reach of children and pets. Do not use for more than 3 days. Serious adverse events have been reported with long term use in dogs. All dogs should undergo a thorough history and exam before initiation of NSAID therapy. Appropriate testing should be conducted prior to administration of an NSAID. Owners should be advised to observe for signs of potential drug toxicity. Stop administration of ONSIOR if the dog experiences inappetence, vomiting or lethargy. Safe use has not been evaluated in dogs younger than 4 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer in conjunction with any other NSAID or corticosteroid. Click here for full prescribing information.
Onsior injection: For subcutaneous use in dogs. Monitor dogs post-injection for reactions. Injection site reactions and anaphylactic reactions have been associated with the use of Onsior injection. Safety has not been demonstrated for intravenous or intramuscular administration. The most common adverse reactions were pain on injection, diarrhea and vomiting.
Onsior Tablets: For oral use in dogs only. Store out of reach of dogs and other pets in a secure location. Do not use in cats. Cats cannot be accurately dosed with the tablet sizes intended to be used in dogs. Dogs should weigh at least 5.5 lbs. The most commonly reported adverse reactions were diarrhea, vomiting, and decreased appetite.
© 2017 Eli Lilly and Company or its affiliates. Onsior, Elanco and the diagonal bar logo are trademarks of Eli Lilly and Company or its affiliates. USCAHMUL01907(1)